RNS Number:6852W
Alliance Pharma PLC
16 May 2007


For immediate release                             16 May 2007



                         ALLIANCE PHARMA PLC
                       ("Alliance" or "the Company")

                                 AGM Statement



Alliance Pharma plc (AIM: APH), the emerging speciality pharmaceutical company, will hold its Annual General Meeting in London this morning.


Michael Gatenby, the Company's Chairman, will make the following comments:


"In our 2006 preliminary results we noted that the phasing of profit in 2007 would be affected by the timing of production transfers of recently acquired brands. Since then we have had to switch the supplier of the Atarax active ingredient following a fire at the previous supplier. Overall demand for our products is satisfactory. However temporary supply shortfalls will adversely affect our first half results. The steps taken to address these issues, and further management action, is expected to restore profitability in the second half to deliver a full year's trading result in excess of last year's.


"Discussions with potential partners for the next stages of development and then the marketing of Posidorm are on-going and, pending their outcome, we are incurring no further development costs. The status of Isprelor remains that Phase III trials have been completed, the results are expected shortly and partnership discussions are on-going.


"I am pleased to report that following the recent acquisition of the marketing rights to Forceval in China the initial shipments of the product have been despatched."



For further information:


Alliance Pharma plc                 + 44 (0) 1249 466966
John Dawson, Chief Executive
www.alliancepharma.co.uk

Buchanan Communications      + 44 (0) 20 7466 5000
Mark Court/Rebecca Skye Dietrich



Notes to editors

About Alliance Pharma

Alliance Pharma, founded in 1996, is an AIM listed emerging speciality pharmaceutical company based in Chippenham, Wiltshire, UK. The company has a strong track record of acquiring the rights to established niche brands and owns, or shares, the rights to 34 branded pharmaceutical products.


Alliance Pharma's products are prescribed in the treatment of a wide range of conditions and include brands used in periodontitis (a serious gum disease), the prevention of heart disease, in Parkinson's disease, in nutrition, in nasal infections, in the treatment of dermatological conditions and in childbirth. Alliance Pharma's sales are mainly prescription driven.  Its products are distributed to hospitals directly and to pharmaceutical wholesalers which service both hospital and retail pharmacies with their prescription requirements.


Alliance Pharma joined the AIM market of the London Stock Exchange in December 2003 and trades under the symbol APH.


This information is provided by RNS 

The company news service from the London Stock Exchange
END

AGMOKAKPCBKKAPD